Recent work, in particular the CAMERA study, has used MRI to study the brains of migraine sufferers and has shown that a higher proportion of these patients exhibit lesions of the brain microvessels than the rest of the population.
Lesions of the…
Hopes that naproxen, a nonsteroidal anti-inflammatory drug (NSAID), or rofecoxib, a COX-2 inhibitor, could slow the progression of Alzheimer’s disease (AD) have been dashed as researchers at Georgetown University Medical Center report in the June 4 Journal of the American Medical Association that neither drug slows the cognitive deterioration that is the hallmark of AD. In addition, more adverse effects were reported in patients taking either drug as compared to the placebo group.